The Most Important Facts About Acelyrin

Small-cap Health Care company Acelyrin has moved -32.4% so far today on a volume of 6,234,450, compared to its average of 1,299,606. In contrast, the S&P 500 index moved 0.0%.

Acelyrin trades -82.18% away from its average analyst target price of $33.0 per share. The 4 analysts following the stock have set target prices ranging from $15.0 to $68.0, and on average have given Acelyrin a rating of buy.

Anyone interested in buying SLRN should be aware of the facts below:

  • Based on its trailing earnings per share of -5.06, Acelyrin has a trailing 12 month Price to Earnings (P/E) ratio of -1.2 while the S&P 500 average is None

  • SLRN has a forward P/E ratio of -1.3 based on its forward 12 month price to earnings (EPS) of $-4.54 per share

  • Its Price to Book (P/B) ratio is 0.78 compared to its sector average of None

  • Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

  • Based in Agoura Hills, the company has 108 full time employees and a market cap of $571.77 Million.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.